At #ESMO26, @DrNeilGross discusses the final analysis of neoadjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma, and what a trial would need to show before complete responders could skip surgery

@myESMO #CSCC #SkinCancer #SkcSM @UTMDAnderson